Your partner for Quantitative Susceptibility Mapping in Europe

Your partner for Quantitative Susceptibility Mapping in Europe

QSM is an innovative patented technique that was initially developed at Cornell University in the team of Professor Yi Wang, and which is now cleared by the Food and Drug Administration for use at 1.5, 3 and 7T MRI field strengths.

Ventio has a special history with this technology since its founder, Ludovic de Rochefort, is one of its inventors. Thus, Ventio has become the exclusive distributor of this technology in SaaS mode (Software-as-a-Service) in Europe for research such that it can be included in your mono or multi-centric clinical studies easily.

Yes, you can have access the patent-protected and FDA-cleared QSM software with Ventio.

Do you want to know more about Ventio’s cloud QSM services? Contact-us or join the QMR Lucca 2022 Joint Workshop on MR phase, magnetic susceptibility and electrical properties mapping held in October in Italy!

In the meanwhile, read more about Ventio’s involvement in flagship applications to advance brain research in Europe.

Do you want an advanced brain biomarker?